No association between a functional NAD(P)H: Quinone oxidoreductase gene polymorphism (Pro187Ser) and tardive dyskinesia

NeuroMolecular Medicine

Volumn 8, Issue 3, 2006, Pages 375-380

  Hori, Hiroko ^a   Shinkai, Takahiro ^a,b   Matsumoto, Chima ^a,c   Ohmori, Osamu ^a,d   Nakamura, Jun ^a  

^a UNIVERSITY OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH   (Japan)

^b MITSUBISHI HEAVY INDUSTRIES LTD   (Japan)

^c NISSAN MOTOR CO   (Japan)

^d Wakato Hospital   (Japan)

Author keywords

Association study; NAD(P)H: quinone oxidoreductase; Oxidative stress; Polymorphism; Schizophrenia; Tardive dyskinesia

Indexed keywords

DOPAMINE; FREE RADICAL; PROLINE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE DEHYDROGENASE (QUINONE); REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; SEMIQUINONE; SERINE;

ADULT; ALLELISM; ARTICLE; FEMALE; GENE; GENETIC POLYMORPHISM; GENETIC PREDISPOSITION; GENOTYPE; HUMAN; JAPAN; MAJOR CLINICAL STUDY; MALE; NERVE INJURY; NQO1 GENE; NUCLEOTIDE SEQUENCE; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; SCHIZOPHRENIA; TARDIVE DYSKINESIA;

ADULT; AGED; DYSKINESIAS; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; JAPAN; MALE; MIDDLE AGED; NAD(P)H DEHYDROGENASE (QUINONE); NADP; POLYMORPHISM, GENETIC; RISK FACTORS;

EID: 33745229249     PISSN: 15351084     EISSN: None     Source Type: Journal    
DOI: 10.1385/NMM:8:3:375     Document Type: Article

References (26)

1. Andreassen O. A. and Jorgensen H. A. (2000) Neurotoxicity associated with neuroleptic-induced oral dyskinesias in rats. Implications for tardive dyskinesia? Prog. Neurobiol. 61, 525-541.
2. Adler L. A., Peselow E., Rotrosen J., et al. (1993) Vitamin E treatment of tardive dyskinesia. Am. J. Psychiatry 150, 1405-1407.
3. Bai Y. M., Yu S. C., and Lin C. C. (2003) Risperidone for severe tardive dyskinesia: a 12-week randomized, double-blind, placebo-controller study. J. Clin. Psychiatry 64, 1342-1348.
4. Barrett J. C., Fry B., Maller J., and Daly M. J. (2005) Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 21, 263-265.
5. Bischot L., Van den Brink G., and Porsius A. J. (1993) Vitamin E in extrapyramidal disorders. Pharm. World Sci. 15, 146-150.
6. Drukarch B. and van Muiswinkel F. L. (2000) Drug treatment of parkinson's disease. Biochem. Pharmacol. 59, 1023-1031.
7. Glazer W. M. (2000) Expected incidence of tardive dyskinesia associated with atypical antipsychotics. J. Clin. Psychiatry 61(Suppl 4), 21-26.
8. Guy W. (1976) Abnormal involuntary movement scale (AIMS), in US Department of Health, Education and Welfare: ECDEU Assessment Manual for Psychopharmacology, revised, US DWEW Publication, Washington, DC, pp. 534-537.
9. Hori H., Ohmori O., Matsumoto C., et al. (2003) NAD(P)H: quinone oxidoreductase (NQO1) gene polymorphism and schizophrenia. Psychiatr. Res. 118, 235-239.
10. Hori H., Ohmori O., Shinkai T., et al. (2000) Manganese superoxide dismutase gene polymorphism and schizophrenia: relation to tardive dyskinesia. Neuropsychopharmacogy 23, 170-177.
11. Kappus H. and Sies H. (1981) Toxic drug effects associated with oxygen metabolism: redox cycling and lipid peroxidation. Experientia 37, 1233-1241.
12. Liou Y. J., Wang Y. C., Lin C. C., et al. (2005) Association analysis of NAD(P)H: quinone oxidoreductase (NQO1) Pro187Ser genetic polymorphism and tardive dyskinesia in patients with schizophrenia in Taiwan. Int. J. Neuropsychopharmacol. 8, 483-486.
13. Lohr J. B. and Caligiuri M. P. (1996) A double-blind placebo-controlled study of vitamin E treatment of tardive dyskinesia. J. Clin. Psychiatry 57, 167-173.
14. Lohr J. B., Kuczenski R., Bracha H. S., Moir M., and Jeste D. V. (1990) Increased indices of free radical activity in the cerebrospinal fluid of patients with tardive dyskinesia. Biol. Psychiatry 28, 535-539.
15. Pae C. U., Yu H. S., Kim J. J., et al. (2004) Quinone oxidoreductase (NQO1) gene polymorphism (607C/T) may be associated with tardive dyskinesia, but not with the development of schizophrenia. Int. J. Neuropsychopharmaco. 7, 495-500.
16. Shale H. and Tanner C. (1996) Pharmacological options for the management of dyskinesia. Drugs 52, 849-860.
17. Sham P. C. and Curtis D. (1995) Monte Carlo tests for associations between disease and alleles at highly polymorphic loci. Ann. Hum. Genet. 59, 97-105.
18. Schooler N. R. and Kane J. M. (1982) Research diagnoses for tardive dyskinesia. Arch. Gen. Psychiatry 39, 486-487.
19. See R. E. (1991) Striatal dopamine metabolism increases during long-term haloperidol administration in rats but shows tolerance in response to acute challenge with raclopride. Neurosci. Lett. 129, 265-268.
20. The International HapMap Consortium. (2003) The International HapMap Project. Nature 426, 789-796.
21. Toru M. (1983) Seishinbunretsubyo no yakuri (Pharmacology in schizophrenia), Chu-gai Igakusha Co., Tokyo.
22. Traver R. D., Horikoshi T., Danenberg K. D., et al. (1992) NAD(P)H: quinone oxidoreductase gene expression in human carcinoma cells: characterization of a mutation which modulates DT-diaphorase activity and mitomycin sensitivity. Cancer Res. 52, 797-802.
23. Traver R. D., Siegel D., Beall H. D., et al. (1997) Characterization of a polymorphism in NAD(P)H: quinone oxidoreductase (DT-diaphorase). Br. J. Cancer 75, 69-75.
24. Tsai G., Goff D. C., Chang R. W., et al. (1998) Markers glutamatergic neurotransmission and oxidative stress associated tardive dyskinesia. Am. J. Psychiatry 155, 1207-1213.
25. Yassa R. and Ananth J. (1981) Familial tardive dyskinesia. Am. J. Psychiatry 138, 1618-1619.
26. Zhang Z., Zhang X., Hou G., Sha W., and Reynolds G. P. (2002) The increased activity of plasma manganese superoxide dismutase in tardive dyskinesia is unrelated to the Ala-9Val polymorphism. J. Psychiatr. Res. 36, 317-324.